References
Takai K, Nikkuni K, Shibuya H, Hashidate H (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 51:320–325 (in Japanese)
Kojima M, Nakamura N, Tsukamoto N, Yokohama A, Itoh H, Kobayashi S, Kashimura M, Masawa N, Nakamura S (2011) Multicentric Castleman’s disease representing effusion at initial clinical presentation: clinicopathological study of seven cases. Lupus 20(1):44–50
Kojima M, Nakamura N, Tsukamoto N et al (2008) Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 16:391–398
Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53(1):57–61. doi:10.3960/jslrt.53.57
Kishimoto T (2010) IL-6: from its discovery to clinical applications. Int Immunol 22(5):347–352
Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226. doi:10.1002/ajh.24242
Liu A et al (2015) Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 3(4):e163–e175
Minicozzi A, Fajgenbaum D (2015) Living life laser-focused: a young man forced to be both doctor and patient. J Clin Res Bioeth 6:252. doi:10.4172/2155-9627.1000252
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Conflict of interest
Dr. Fajgenbaum has received a research grant/funding from Janssen pharmaceuticals. The authors Drs. Behnia, Elojeimy, and Matesan declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Behnia, F., Elojeimy, S., Matesan, M. et al. Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome. Ann Hematol 96, 497–500 (2017). https://doi.org/10.1007/s00277-016-2875-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2875-8